IBDEI21A ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34076,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,34076,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,34077,0)
 ;;=N07.3^^154^1722^26
 ;;^UTILITY(U,$J,358.3,34077,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34077,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34077,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,34077,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,34078,0)
 ;;=N07.4^^154^1722^23
 ;;^UTILITY(U,$J,358.3,34078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34078,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34078,1,4,0)
 ;;=4^N07.4
 ;;^UTILITY(U,$J,358.3,34078,2)
 ;;=^5015563
 ;;^UTILITY(U,$J,358.3,34079,0)
 ;;=N07.5^^154^1722^27
 ;;^UTILITY(U,$J,358.3,34079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34079,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,34079,1,4,0)
 ;;=4^N07.5
 ;;^UTILITY(U,$J,358.3,34079,2)
 ;;=^5015564
 ;;^UTILITY(U,$J,358.3,34080,0)
 ;;=N07.6^^154^1722^22
 ;;^UTILITY(U,$J,358.3,34080,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34080,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,34080,1,4,0)
 ;;=4^N07.6
 ;;^UTILITY(U,$J,358.3,34080,2)
 ;;=^5015565
 ;;^UTILITY(U,$J,358.3,34081,0)
 ;;=N07.7^^154^1722^28
 ;;^UTILITY(U,$J,358.3,34081,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34081,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,34081,1,4,0)
 ;;=4^N07.7
 ;;^UTILITY(U,$J,358.3,34081,2)
 ;;=^5015566
 ;;^UTILITY(U,$J,358.3,34082,0)
 ;;=N07.8^^154^1722^31
 ;;^UTILITY(U,$J,358.3,34082,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34082,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
 ;;^UTILITY(U,$J,358.3,34082,1,4,0)
 ;;=4^N07.8
 ;;^UTILITY(U,$J,358.3,34082,2)
 ;;=^5015567
 ;;^UTILITY(U,$J,358.3,34083,0)
 ;;=N07.9^^154^1722^32
 ;;^UTILITY(U,$J,358.3,34083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34083,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
 ;;^UTILITY(U,$J,358.3,34083,1,4,0)
 ;;=4^N07.9
 ;;^UTILITY(U,$J,358.3,34083,2)
 ;;=^5015568
 ;;^UTILITY(U,$J,358.3,34084,0)
 ;;=N08.^^154^1722^21
 ;;^UTILITY(U,$J,358.3,34084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34084,1,3,0)
 ;;=3^Glomerular disorders in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,34084,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,34084,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,34085,0)
 ;;=C90.00^^154^1723^9
 ;;^UTILITY(U,$J,358.3,34085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34085,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,34085,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,34085,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,34086,0)
 ;;=C90.01^^154^1723^8
 ;;^UTILITY(U,$J,358.3,34086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34086,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,34086,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,34086,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,34087,0)
 ;;=C90.02^^154^1723^7
 ;;^UTILITY(U,$J,358.3,34087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34087,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,34087,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,34087,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,34088,0)
 ;;=E11.29^^154^1723^19
 ;;^UTILITY(U,$J,358.3,34088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34088,1,3,0)
 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,34088,1,4,0)
 ;;=4^E11.29
